Cystic fibrosis in Vietnam and Southeast Asia: underdiagnosis and genetic spectrum
- PMID: 40465100
- PMCID: PMC12202266
- DOI: 10.1007/s12687-025-00807-1
Cystic fibrosis in Vietnam and Southeast Asia: underdiagnosis and genetic spectrum
Abstract
Recent reports confirm that cystic fibrosis (CF) is a global disease. In Asian populations, both the spectrum of cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and the clinical course differ from those observed in Western populations. Although the recognition of CF is increasing in South Asia, comprehensive data from Southeast Asian countries remain sparse. The underdiagnosis of CF in Southeast Asia is attributed to limited awareness among healthcare professionals and restricted access to sweat chloride testing. Until 2021, CF had not been documented in the indigenous population of Vietnam. This study presents the first three confirmed cases of CF in native Vietnamese individuals. Additionally, a literature review of CF cases reported across Southeast Asia was conducted to provide insights into its prevalence and variations in CFTR mutation profiles within the region. A total of 50 cases were identified, distributed across Malaysia (30 cases), Thailand (8), the Philippines (6), Vietnam (5), and Indonesia (1), revealing a mutation spectrum distinct from that observed in Caucasian populations. The most common mutations included p.Phe508del and p.Ile1295PhefsX32, each found in 11.5% of cases. These findings highlight the need for increased clinical awareness, expanded access to sweat chloride testing, and the establishment of CF centers and regional CF registries to better understand and manage CF in Southeast Asia.
Keywords: CFTR; Cystic fibrosis; Genetic spectrum; Southeast Asia; Vietnam.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Ethical approval: This article did not contain any studies with human or animal subjects performed by any of the authors. Informed consent was obtained from our patients for inclusion in the study. Competing interests: The authors declare no competing interests.
Similar articles
-
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.Cochrane Database Syst Rev. 2023 Mar 3;3(3):CD012040. doi: 10.1002/14651858.CD012040.pub3. Cochrane Database Syst Rev. 2023. PMID: 36866921 Free PMC article.
-
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD010966. doi: 10.1002/14651858.CD010966.pub4. Cochrane Database Syst Rev. 2023. PMID: 37983082 Free PMC article.
-
Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis.Cochrane Database Syst Rev. 2023 Apr 12;4(4):CD001401. doi: 10.1002/14651858.CD001401.pub4. Cochrane Database Syst Rev. 2023. PMID: 37042825 Free PMC article.
-
Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease.Cochrane Database Syst Rev. 2016 Jun 17;2016(6):CD005599. doi: 10.1002/14651858.CD005599.pub5. Cochrane Database Syst Rev. 2016. PMID: 27314455 Free PMC article.
-
Inhaled mannitol for cystic fibrosis.Cochrane Database Syst Rev. 2018 Feb 9;2(2):CD008649. doi: 10.1002/14651858.CD008649.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2020 May 1;5:CD008649. doi: 10.1002/14651858.CD008649.pub4. PMID: 29424930 Free PMC article. Updated.
References
-
- Ahmed S, Cheok G, Goh AE et al (2020) Cystic fibrosis in Asia. Pediatr Respirol Crit Care Med 4(1):8–12. 10.4103/prcm.prcm_5_20
-
- Cao-Pham HG, Nguyen HP, Le TTT (2022) Cystic fibrosis in Vietnam: a case report. Ho Chi Minh City J Med 26(2):54–57
Publication types
LinkOut - more resources
Full Text Sources